** ASX-listed shares of Aroa Biosurgery rise as much as 15.4% to A$0.6, their highest since Aug. 12
** NZ's Medical products maker expects to be operating cash flow positive in the second half of FY25
** Co says FY25 normalised EBITDA guidance maintained at NZ$2 mln ($1.21 mln) to NZ$6 mln
** Says, FY25 revenue guidance maintained between NZ$80 mln and NZ$87 mln
** ARX to release financial results for H1 FY25 on Nov. 26
** Stock down 30.7% YTD
($1 = 1.6543 New Zealand dollars)
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments